Tandem Diabetes Care (TNDM) Research & Development (2013 - 2026)

Tandem Diabetes Care (TNDM) has reported Research & Development for 14 consecutive years, with $46.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 2.47% year-over-year to $46.9 million; the trailing twelve-month figure through Jun 2026 stood at $187.7 million (down 6.89% YoY), and the FY2025 full-year result was $193.1 million, down 2.9% from the prior year.
• Research & Development rose to $46.9 million in Q2 2026 per TNDM's latest filing, from $46.0 million in the prior quarter.
• Across five years, Research & Development topped out at $52.2 million in Q4 2024 and bottomed at $33.2 million in Q1 2022.
• Historically, Research & Development has averaged $44.1 million across 5 years, with a median of $46.1 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Research & Development surged 84.62% in 2022, then retreated 11.75% in 2025.
• Over 5 years, Research & Development stood at $35.6 million in 2022, then gained by 19.72% to $42.6 million in 2023, then increased by 22.52% to $52.2 million in 2024, then declined by 11.75% to $46.1 million in 2025, then increased by 1.88% to $46.9 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $46.9 million, $46.0 million, and $46.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.